Fully-automated estimation of upper cervical cord cross-sectional area using pontomedullary junction referencing in multiple sclerosis.

IF 2.5
Frontiers in neuroimaging Pub Date : 2025-11-04 eCollection Date: 2025-01-01 DOI:10.3389/fnimg.2025.1681669
Roberto Masciullo, Annine Sutter, Rosaria Sacco, Nicola Pinna, Daniela Distefano, Emanuele Pravatà, Giulia Mallucci, Alessandro Cianfoni, Claudio Gobbi, Chiara Zecca, Giulio Disanto
{"title":"Fully-automated estimation of upper cervical cord cross-sectional area using pontomedullary junction referencing in multiple sclerosis.","authors":"Roberto Masciullo, Annine Sutter, Rosaria Sacco, Nicola Pinna, Daniela Distefano, Emanuele Pravatà, Giulia Mallucci, Alessandro Cianfoni, Claudio Gobbi, Chiara Zecca, Giulio Disanto","doi":"10.3389/fnimg.2025.1681669","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Spinal cord cross-sectional area (CSA) is a biomarker of disability in multiple sclerosis (MS). Vertebral-based CSA suffers from anatomical variability and positional bias.</p><p><strong>Objectives: </strong>To evaluate a fully automated PMJ-referenced approach, as implemented in the open-source Spinal Cord Toolbox, to assess cervical cord CSA at a fixed distance from the pontomedullary junction (PMJ) in MS.</p><p><strong>Methods: </strong>Retrospective study performed at the MS center of Lugano (Switzerland). Inclusion criteria were treatment with natalizumab or ocrelizumab and absence of clinical/radiological disease activity over ≥2 years. CSA at 64 mm caudal to the PMJ (CSA PMJ) and at C2-C3 vertebral level (CSA C2-C3) were calculated using the Spinal Cord Toolbox.</p><p><strong>Results: </strong>Seventy-five MS patients [females = 44 (58.7%), age = 45.1 (36.7-53.8) years, natalizumab = 36 (48%), ocrelizumab = 39 (52%)] were included. Median CSA PMJ and CSA C2-C3 were 57.7 (53.1-62.1) and 58.1 (53.2-62.6) mm<sup>2</sup>, respectively. The two measures were highly correlated (rho = 0.95, <i>p</i> < 0.001), with some exceptions related to errors in vertebral labelling in CSA C2-C3 assessments. PMJ was correctly identified in all subjects. CSA PMJ measures were negatively associated with disability (<i>β</i> = -0.08, <i>p</i> = 0.002), independent of age and sex.</p><p><strong>Conclusion: </strong>Automated measurement of spinal cord CSA at fixed distance from the PMJ is applicable in MS, performs better than vertebral-based CSA, and correlates with neurological disability.</p>","PeriodicalId":73094,"journal":{"name":"Frontiers in neuroimaging","volume":"4 ","pages":"1681669"},"PeriodicalIF":2.5000,"publicationDate":"2025-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12623166/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in neuroimaging","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fnimg.2025.1681669","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Spinal cord cross-sectional area (CSA) is a biomarker of disability in multiple sclerosis (MS). Vertebral-based CSA suffers from anatomical variability and positional bias.

Objectives: To evaluate a fully automated PMJ-referenced approach, as implemented in the open-source Spinal Cord Toolbox, to assess cervical cord CSA at a fixed distance from the pontomedullary junction (PMJ) in MS.

Methods: Retrospective study performed at the MS center of Lugano (Switzerland). Inclusion criteria were treatment with natalizumab or ocrelizumab and absence of clinical/radiological disease activity over ≥2 years. CSA at 64 mm caudal to the PMJ (CSA PMJ) and at C2-C3 vertebral level (CSA C2-C3) were calculated using the Spinal Cord Toolbox.

Results: Seventy-five MS patients [females = 44 (58.7%), age = 45.1 (36.7-53.8) years, natalizumab = 36 (48%), ocrelizumab = 39 (52%)] were included. Median CSA PMJ and CSA C2-C3 were 57.7 (53.1-62.1) and 58.1 (53.2-62.6) mm2, respectively. The two measures were highly correlated (rho = 0.95, p < 0.001), with some exceptions related to errors in vertebral labelling in CSA C2-C3 assessments. PMJ was correctly identified in all subjects. CSA PMJ measures were negatively associated with disability (β = -0.08, p = 0.002), independent of age and sex.

Conclusion: Automated measurement of spinal cord CSA at fixed distance from the PMJ is applicable in MS, performs better than vertebral-based CSA, and correlates with neurological disability.

Abstract Image

Abstract Image

Abstract Image

在多发性硬化症中使用桥髓连接参考全自动估计上颈髓横断面积。
背景:脊髓横断面积(CSA)是多发性硬化症(MS)残疾的生物标志物。椎骨为基础的CSA存在解剖变异和位置偏差。目的:评价在开源脊髓工具箱中实现的全自动PMJ参考方法,以评估MS中离桥髓连接处(PMJ)固定距离处的颈髓CSA。方法:在Lugano(瑞士)MS中心进行回顾性研究。纳入标准是接受natalizumab或ocrelizumab治疗,且无临床/放射学疾病活动≥2 年。使用脊髓工具箱计算PMJ尾部64 mm的CSA (CSA PMJ)和C2-C3椎体水平(CSA C2-C3)。结果:纳入75例MS患者[女性 = 44(58.7%),年龄 = 45.1(36.7-53.8)岁,natalizumab = 36 (48%),ocrelizumab = 39(52%)]。中位CSA PMJ和CSA C2-C3分别为57.7(53.1-62.1)和58.1 (53.2-62.6)mm2。两项指标高度相关(rho = 0.95,p β = -0.08,p = 0.002),与年龄和性别无关。结论:在距PMJ固定距离处自动测量脊髓CSA适用于多发性硬化症,比基于椎骨的CSA效果更好,且与神经功能障碍相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书